FDA approves first-in-class Mimrylo for rare blood cancer on August 31, 2026 Approved Hematologic Neoplasms hepcidin Infrequent mimetics Mimrylo Polycythemia rusfertide Takeda United States Food and Drug Administration vera VERIFY trial +
Zealand Sells Rights to Takeda’s Blood Cancer Drug for $100M Ahead of FDA Approval Decision on August 13, 2026 Approved goal Hematologic Neoplasms Hepcidin Mimetic PTG-300 PDUFA Pharma Polycythemia royalty rusfertide Takeda United States Food and Drug Administration Vera Zealand Pharma +
Gene‑silencing drug divesiran posts strong Phase 2 win in rare blood cancer on August 11, 2026 divesiran gene-silencing Hematocrit procedure Hematologic Neoplasms Hepcidin Infrequent Polycythemia RNA, Small Interfering rusfertide SANRECO Silence Therapeutics ' Takeda TMPRSS6 gene Venous blood sampling Vera +